Palvella Therapeutics (PVLA) Enterprise Value: 2013-2024
Historic Enterprise Value for Palvella Therapeutics (PVLA) over the last 11 years, with Dec 2024 value amounting to $15.8 million.
- Palvella Therapeutics' Enterprise Value rose 848.08% to $15.8 million in Q4 2024 from the same period last year, while for Dec 2024 it was $15.8 million, marking a year-over-year increase of 108.95%. This contributed to the annual value of $15.8 million for FY2024, which is 848.08% up from last year.
- Latest data reveals that Palvella Therapeutics reported Enterprise Value of $15.8 million as of Q4 2024, which was up 106.22% from $7.7 million recorded in Q3 2024.
- In the past 5 years, Palvella Therapeutics' Enterprise Value ranged from a high of $219.8 million in Q3 2021 and a low of -$51.3 million during Q2 2023.
- Over the past 3 years, Palvella Therapeutics' median Enterprise Value value was $9.8 million (recorded in 2024), while the average stood at $13.9 million.
- As far as peak fluctuations go, Palvella Therapeutics' Enterprise Value slumped by 383.92% in 2023, and later surged by 848.08% in 2024.
- Over the past 5 years, Palvella Therapeutics' Enterprise Value (Quarterly) stood at $69.5 million in 2020, then skyrocketed by 122.52% to $154.6 million in 2021, then tumbled by 88.22% to $18.2 million in 2022, then tumbled by 90.83% to $1.7 million in 2023, then surged by 848.08% to $15.8 million in 2024.
- Its last three reported values are $15.8 million in Q4 2024, $7.7 million for Q3 2024, and -$1.6 million during Q2 2024.